Letícia Torres da Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Letícia Torres da Silva has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Filipe Pereira Sarmento
Department of Neurological Sciences, Rush University, Chicago, IL
3 shared publications - Jorge Resende Gondim Jasmineiro Pitanga
Departamento de Microbiología, Parasitología e Inmunología, Universidad de Buenos Aires, Argentina
3 shared publications - Murilo Marmori Cruccioli
Departamento de Medicina, Universidade Evangélica de Goiás, Anápolis, Brazil
3 shared publications - Pedro Henrique Teixeira Carneiro
Departamento de Medicina, Universidade de Santo Amaro, São Paulo, Brazil
3 shared publications - Marla Resende Gondim Jasmineiro Pitanga
Departamento de Medicina, Instituto Universitario de Ciencias de la Salud Fundación Barceló, Buenos Aires, Argentina
2 shared publications - Yasmin Bastos Faller
Universidad de Buenos Aires, Departamento de Medicina, Buenos Aires, Argentina
2 shared publications
Latest Publications
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (2)
Albendazole-Praziquantel Dual Therapy Compared With Albendazole Monotherapy in Neurocysticercosis
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (2)
Albendazole-Praziquantel Dual Therapy Compared With Albendazole Monotherapy in Neurocysticercosis
- 1 February 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (1) , e200567
Albendazole-Praziquantel Dual Therapy Compared With Albendazole Monotherapy in Neurocysticercosis
Neurocysticercosis is the most common parasitic infection of the CNS and remains a significant, yet often neglected, public health issue in endemic regions. High-quality evidence suggests that albendazole monotherapy leads to superior clinical outcomes compared with placebo or praziquantel. However, there is still insufficient evidence regarding the efficacy and safety of combined albendazole-praziquantel therapy. This systematic review and meta-analysis aims to compare combined antiparasitic therapy with albendazole and praziquantel with albendazole monotherapy, evaluating whether dual therapy offers superior therapeutic benefits in the management of neurocysticercosis while maintaining an acceptable safety profile. We searched MEDLINE, Embase, and the Cochrane Library for randomized controlled trials (RCTs) published until April 2024 that compared combined albendazole-praziquantel therapy with albendazole monotherapy for the treatment of neurocysticercosis. Statistical analysis was performed using Review Manager 5.4.1, with odds ratios (ORs) and 95% confidence intervals (CIs) reported. A random-effects model was applied to all end points. The risk of bias was assessed for each study, and the certainty of evidence was evaluated using the GRADE approach. Five RCTs were included, comprising a total of 320 patients, 49% of whom received combined therapy. Complete cyst resolution was significantly more frequent in patients treated with combined albendazole-praziquantel therapy compared with albendazole monotherapy (OR = 3.06; 95% CI [1.81-5.19]; p = 0.0001; I 2 = 5%; high-certainty evidence). In a subgroup analysis restricted to patients with 1-2 cysts (248 patients), no statistically significant difference in complete cyst resolution was observed (OR = 1.98; 95% CI [0.92-4.27]; p = 0.08; I 2 = 34%; very-low-certainty evidence). There was no significant difference in seizure recurrence between treatment strategies (OR = 1.28, 95% CI [0.56-2.91], p = 0.55, I 2 = 0%; moderate-certainty evidence). Similarly, the incidence of adverse effects did not differ significantly between groups (OR = 1.40, 95% CI [0.72-2.72], p = 0.30, I 2 = 0%; moderate-certainty evidence). This systematic review and meta-analysis demonstrated a threefold increase in complete cyst resolution among patients receiving combined therapy, suggesting its superiority over albendazole monotherapy for the management of neurocysticercosis. In addition, no significant differences were observed between treatment strategies regarding seizure or adverse events.
- 1 February 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (1) , e200567
Albendazole-Praziquantel Dual Therapy Compared With Albendazole Monotherapy in Neurocysticercosis
Neurocysticercosis is the most common parasitic infection of the CNS and remains a significant, yet often neglected, public health issue in endemic regions. High-quality evidence suggests that albendazole monotherapy leads to superior clinical outcomes compared with placebo or praziquantel. However, there is still insufficient evidence regarding the efficacy and safety of combined albendazole-praziquantel therapy. This systematic review and meta-analysis aims to compare combined antiparasitic therapy with albendazole and praziquantel with albendazole monotherapy, evaluating whether dual therapy offers superior therapeutic benefits in the management of neurocysticercosis while maintaining an acceptable safety profile. We searched MEDLINE, Embase, and the Cochrane Library for randomized controlled trials (RCTs) published until April 2024 that compared combined albendazole-praziquantel therapy with albendazole monotherapy for the treatment of neurocysticercosis. Statistical analysis was performed using Review Manager 5.4.1, with odds ratios (ORs) and 95% confidence intervals (CIs) reported. A random-effects model was applied to all end points. The risk of bias was assessed for each study, and the certainty of evidence was evaluated using the GRADE approach. Five RCTs were included, comprising a total of 320 patients, 49% of whom received combined therapy. Complete cyst resolution was significantly more frequent in patients treated with combined albendazole-praziquantel therapy compared with albendazole monotherapy (OR = 3.06; 95% CI [1.81-5.19]; p = 0.0001; I 2 = 5%; high-certainty evidence). In a subgroup analysis restricted to patients with 1-2 cysts (248 patients), no statistically significant difference in complete cyst resolution was observed (OR = 1.98; 95% CI [0.92-4.27]; p = 0.08; I 2 = 34%; very-low-certainty evidence). There was no significant difference in seizure recurrence between treatment strategies (OR = 1.28, 95% CI [0.56-2.91], p = 0.55, I 2 = 0%; moderate-certainty evidence). Similarly, the incidence of adverse effects did not differ significantly between groups (OR = 1.40, 95% CI [0.72-2.72], p = 0.30, I 2 = 0%; moderate-certainty evidence). This systematic review and meta-analysis demonstrated a threefold increase in complete cyst resolution among patients receiving combined therapy, suggesting its superiority over albendazole monotherapy for the management of neurocysticercosis. In addition, no significant differences were observed between treatment strategies regarding seizure or adverse events.
- 25 December 2025
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 16 (5) , 1-7
Amantadine for multiple sclerosis-related fatigue: a systematic review and meta-analysis of randomized controlled trials
Fatigue affects up to 95% of individuals with multiple sclerosis (MS), significantly impairing daily functioning. Management is multidisciplinary, and although amantadine lacks U.S. FDA approval for this indication, it remains the most commonly prescribed pharmacologic option despite inconsistent supporting evidence. This systematic review and meta-analysis evaluated the effectiveness of amantadine for MS-related fatigue. We searched MEDLINE, EMBASE, and Web of Science for randomized controlled trials (RCTs) comparing amantadine to placebo in the treatment of MS-related fatigue. Statistical analyses were conducted using R. Standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess fatigue severity and adverse effects incidence, respectively. A random-effects model was applied to all analyses. A total of nine RCTs were included, involving 601 patients, 66% of whom received amantadine. Amantadine use was not associated with a significant reduction in fatigue severity compared to placebo (SMD -0.22; [95% CI -0.72; 0.27]; p = 0.37). However, it was associated with higher odds of insomnia (OR = 2.33; [95% CI 1.27; 4.29]; p = 0.006). This meta-analysis suggests that amantadine is not effective for treating MS-related fatigue and is associated with an increased risk of adverse effects, particularly insomnia. These results cast doubt on its continued first-line use.
- 25 December 2025
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 16 (5) , 1-7
Amantadine for multiple sclerosis-related fatigue: a systematic review and meta-analysis of randomized controlled trials
Fatigue affects up to 95% of individuals with multiple sclerosis (MS), significantly impairing daily functioning. Management is multidisciplinary, and although amantadine lacks U.S. FDA approval for this indication, it remains the most commonly prescribed pharmacologic option despite inconsistent supporting evidence. This systematic review and meta-analysis evaluated the effectiveness of amantadine for MS-related fatigue. We searched MEDLINE, EMBASE, and Web of Science for randomized controlled trials (RCTs) comparing amantadine to placebo in the treatment of MS-related fatigue. Statistical analyses were conducted using R. Standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess fatigue severity and adverse effects incidence, respectively. A random-effects model was applied to all analyses. A total of nine RCTs were included, involving 601 patients, 66% of whom received amantadine. Amantadine use was not associated with a significant reduction in fatigue severity compared to placebo (SMD -0.22; [95% CI -0.72; 0.27]; p = 0.37). However, it was associated with higher odds of insomnia (OR = 2.33; [95% CI 1.27; 4.29]; p = 0.006). This meta-analysis suggests that amantadine is not effective for treating MS-related fatigue and is associated with an increased risk of adverse effects, particularly insomnia. These results cast doubt on its continued first-line use.
- 13 November 2025
- Published by Wiley in Immunological Reviews
- Vol. 336 (1) , e70073
Dendritic Cells: Orchestrators of Immune Responsiveness and Tolerance
Dendritic cells (DCs) are central regulators of the delicate balance between protective immune responses to pathogens and cancer, and immunopathology. This review explores the phenotypic and functional heterogeneity of DCs and their specialized roles in regulating the immune response, with a focus on pathways that confer tolerogenic properties to DCs. Furthermore, we discuss emerging strategies for the therapeutic induction of a tolerogenic phenotype in DCs in the setting of autoimmune diseases. A better understanding of the molecular mechanisms that control the tolerogenic phenotype of DCs may open new avenues for the development of efficacious and safe immunotherapies for autoimmune, allergic, and chronic inflammatory diseases.
- 13 November 2025
- Published by Wiley in Immunological Reviews
- Vol. 336 (1) , e70073
Dendritic Cells: Orchestrators of Immune Responsiveness and Tolerance
Dendritic cells (DCs) are central regulators of the delicate balance between protective immune responses to pathogens and cancer, and immunopathology. This review explores the phenotypic and functional heterogeneity of DCs and their specialized roles in regulating the immune response, with a focus on pathways that confer tolerogenic properties to DCs. Furthermore, we discuss emerging strategies for the therapeutic induction of a tolerogenic phenotype in DCs in the setting of autoimmune diseases. A better understanding of the molecular mechanisms that control the tolerogenic phenotype of DCs may open new avenues for the development of efficacious and safe immunotherapies for autoimmune, allergic, and chronic inflammatory diseases.